To investigate mechanism(s) by which mutations in the olfactomedin domain of myocilin (MYOC), also known as the trabecular meshwork-induced glucocorticoid response (TIGR) gene, cause autosomal dominant open-angle glaucoma, the structure and properties of wild-type (WT) MYOC protein were examined, when expressed alone or simultaneously with the Q368X or K423E disease-associated polypeptides. METHODS. Myocilin was analyzed in human aqueous humor and human trabecular meshwork (HTM) tissues. COS-7 and immortalized human trabecular meshwork (iHTM) cell lines were transfected with expression vectors encoding WT MYOC, mutated, and/or epitope-tagged cDNAs. MYOC proteins were characterized by double-epitope tagging procedures and/or Western blot analysis. RESULTS. MYOC polypeptides formed highly similar oligomers in aqueous humor, HTM tissues, transfected COS-7, and iHTM cell lines. These complexes ranged in size from 116 kDa to more than 200 kDa. The smallest complex, approximately 116 kDa, resulted from dimerization between two MYOC monomers. Expression of a 150-kDa complex was strongest in aqueous humor. Cotransfections of the WT construct with either the Q368X or K423E cDNA produced MYOC WT /MYOC mutant heterodimers and higher molecular weight hetero-oligomeric complexes. WT homo-oligomeric complexes were secreted in the extracellular media of both cell lines whereas the Q368X and K423E mutant/mutant homomultimers and heteromeric WT/mutant oligomers remained sequestered intracellularly. 
G laucoma encompasses a complex of ocular disease entities characterized by optic neuropathy and progressive loss of visual fields. After cataracts, the disorder is the second leading cause of blindness, affecting more than 67 million people worldwide. 1, 2 Of all the different forms of glaucoma, primary open-angle glaucoma (POAG; Mendelian Inheritance in Man [MIM] 137760) 3 occurs most frequently, with approximately 33 million cases in 2000. 4, 5 POAG shows genetic heterogeneity, 6 -8 and seven loci have been mapped for the disorder: GLC1A to GLC1G. Only two of the GLC1 genes have been characterized: the trabecular meshwork-inducible glucocorticoid response (TIGR) gene, 9 also known as myocilin (MYOC), 10 at GLC1A, and optineurin (OPTN) at GLC1E.
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More than 40 MYOC mutations have been reported. Most of the disease-causing mutations are located within exon 3 of MYOC 12, 13 (amino acids [aa]) 246-504) in a domain highly homologous to olfactomedin. 14 In affected families, mutations cause autosomal dominant juvenile-(juvenile-onset open-angle glaucoma [JOAG] ) and/or autosomal dominant adult-onset open-angle glaucoma. 9, 12, [15] [16] [17] [18] [19] [20] [21] [22] These variations were associated with POAG in approximately 2% to 4% of patients of glaucoma in the different populations tested. 12, 13, 22, 23 Phenotype-genotype correlation studies have demonstrated that MYOC Q368X is the most frequently observed variation causing late-onset POAG, with an average age at diagnosis of 59 years, whereas, the Y437H mutation induces early-onset glaucoma with an average age of onset of 20 years. 13, 21 Using a very large French-Canadian pedigree, we also demonstrated that the K423E mutation displays wide variable phenotypic expressivity, ranging from early-to late-onset POAG. 20 Four mutant homozygotes were further detected in this kindred; none of them manifested any symptoms of the disorder. As of March 2004, these homozygotes remained normal. Meiotic reversion, parent-of-origin-dependent effects, and reduced penetrance of the mutant allele were ruled out in these asymptomatic mutant homozygotes. MYOC K423E , therefore, caused the first autosomal dominant heterozygote-specific phenotype in humans. 20 The MYOC gene encodes a 504-aa polypeptide with a theoretical molecular mass of 56.9 kDa. In ocular tissues, the MYOC protein was mainly localized within the trabecular meshwork, the Schlemm's canal, the sclera, the ciliary body, the retina, and the optic nerve. 24, 25 The function of the polypeptide is still unknown, but its colocalization with extracellular matrix proteins such, as fibronectin, laminin, or type IV collagen, 26, 27 supports that at least part of its role is played out in the extracellular environment. Indeed, myocilin is secreted in aqueous humor (AH), 28 -31 and experiences with ocular and nonocular cell lines have shown that the protein is released in the extracellular media. 14, 30, [32] [33] [34] In contrast, the glaucomacausing myocilin mutations that have been tested prevent the mutant polypeptides from being secreted 30, 35 and decrease the expressed protein's solubility in Triton X-100. 36 Molecular mechanisms leading to dominance have been classified into eight categories. 37 In humans, one of these categories is dominant negative effects often caused by mutations in multimeric proteins that rely on oligomerization for their activity. 37 Two features located in the myocilin NH 2 -terminal may be involved in protein-protein interactions and may be relevant to the autosomal dominant mode of segregation of glaucoma: a coiled-coil motif between residues 78 and 105 and a leucine zipper containing seven leucine motifs at aa 117-166. 14, 28 Nine cysteine residues distributed along the polypeptide may also be involved in intermolecular disulfide bonding.
To investigate the role of myocilin mutations in the pathogenesis of autosomal dominant POAG, we studied potential interactions between the wild-type protein and the Q368X or K423E variants. We report that WT myocilin was detected as oligomers ranging from approximately 116 kDa to more than 200 kDa in human trabecular meshwork (HTM), transiently transfected cell lines, and extracellular media of this tissue and cell lines. The Q368X and K423E glaucoma disease-causing mutants were found to interact with WT myocilin, producing heteromeric complexes that were not exported extracellularly. Mutant Q368X and K423E homomeric complexes also remained sequestered within transfected cell lines. The pathologic role of myocilin mutations may thus be linked to intracellular sequestration of MYOC mutant /MYOC mutant and/or MYOC WT /MYOC mutant complexes.
MATERIALS AND METHODS

Trabecular Meshwork Tissues and Aqueous Humor
Pairs of human eyes were obtained less than 24 hours after death from the Centre Hospitalier de l'Université Laval (CHUL) eye bank after approval of the CHUL ethics board in agreement with the tenets of the Declaration of Helsinki. AH was harvested with a 27 1 ⁄ 2-gauge syringe and frozen at Ϫ80°C until needed. HTMs dissected from eyes after enucleation were stored at Ϫ80°C in Triton lysis buffer (0.5% Triton X-100, 50 mM 
Construction of Myocilin-Expression Vector, Site-Directed Mutagenesis, and Epitope Tagging
To create a eukaryotic expression vector encoding the human wildtype myocilin cDNA, a 1831-bp HindIII/NotI fragment encompassing 36 bp of the 5Ј untranslated region, the full-length 1512-bp open reading frame (ORF), and 188 bp of the 3Ј untranslated region of MYOC WT was subcloned directionally into the HindIII/NotI sites of the plasmid pRcCMV (Invitrogen, Burlington, Ontario, Canada). The myocilin-expression vector was named pRc-MYOC. Tagged MYOC cDNAs were prepared by using the overlap extension method in combination with the polymerase chain reaction. 39 Overlapping oligonucleotides used were 5Ј-TTT-TCC-TTT-TGC-GGC-CGC-TCA-ATT-CAG-ATC-CTC-TTC-TGA-GAT-GAG-TTT-TTG-TTC- CAT-CTT-GGA-GAG-CTT-GAT-GTC-ATA-AGT-3Ј and 5Ј-TTT-TCC-TTT-TGC-GGC-CGC-TCA-GTG-ATG-ATG-GTG-GTG-ATG-CAT-CTT-GGA-GAG-CTT-GAT-GTC-ATA-AGT-3Ј for the C-Mycand His 6 -tagged cDNAs, respectively (overlapping sequences are italic). Flanking oligonucleotide used for both constructs was 5Ј-CCC-ACT-GCT-TAA-CTG-GCT-TAT-CG-3Ј. The resultant PCR products were cut with the restriction enzymes HindIII and NotI and cloned into pRcCMV digested with the same enzymes. Tags were placed at the carboxyl terminus end of MYOC cDNA, and the tagged plasmids were named pRc-MYOC WT Cell Culture, Transfection, and Cellular Tissue Preparation COS-7 cells (ATCC, Manassas, VA) were grown in high-glucose DMEM complemented with 10% fetal bovine serum, 100 U/mL penicillin, 100 g/mL streptomycin, and 200 M L-glutamine (Invitrogen) and incubated at 37°C in a humidified chamber with 5% CO 2 . Immortalized human trabecular meshwork (iHTM) cells, established from a 30-yearold individual without glaucoma, as previously described, 40 were grown in similar conditions except that low-glucose DMEM was used. This cell line did not produce detectable endogenous myocilin, and the protein was not induced by glucocorticoid treatments, unlike human primary trabecular meshwork cell lines in which MYOC was upregulated by dexamethasone. 34 COS-7 and iHTM cells were plated at densities of 1.5 ϫ 10 5 or 1.2 ϫ 10 6 cells per 35-or 100-mm culture dishes, respectively. Transient transfections were performed 16 hours later with transfection reagent (FuGene 6; Roche) in conditions recommended by the manufacturer. We used 2 L of the reagent and 1 g of total plasmid for COS-7 cells, whereas a ratio of 4 L for 2 g was used for iHTM cells (35-mm culture dish). Forty-eight hours after transfection, an aliquot of the extracellular medium was taken before the cells were washed twice with ice-cold PBS and scrapped in Triton X-100 lysis buffer using a rubber policeman. Because myocilin may bind to membranes, 14 this procedure efficiently measured the released form of the protein. Cellular extracts were processed as for HTM tissues before protein analysis.
Glycosidases and Tunicamycin Treatments
To prevent N-glycosylation, tunicamycin (1 g/mL medium) was added to the COS-7 culture medium 12 hours after transfection. To hydrolyze potential O-or N-glycans present on MYOC, O-glycosidase (1 mU/20 g proteins; incubated at 37°C for 1 hour; Roche) or PNGase F (500 U/20 g proteins; according to the manufacturer's protocol; New England BioLabs, Beverly, MA) was added, respectively, to selected cell lysates.
Western Blot Analysis
AH and culture media were directly mixed with LDS sample buffer (final concentration: glycerol 1.09 M, Tris-base 141 mM, Tris-HCl 106 mM, LDS 73 mM, EDTA 0.51 mM, serva blue G250 0.22 mM, and phenol red 0.175 mM; NuPAGE; Invitrogen) as for the cellular extracts (total proteins). Protein samples, heated at 70°C for 10 minutes, were resolved on Tris-acetate 7% or 3% to 8% precast protein gels (NuPAGE; Invitrogen) and transferred onto nitro-cellulose membrane (BioTrace NT; PALL Corporation, Mississauga, Ontario, Canada) with a transblotting module (Mini Trans-Blot; Bio-Rad). Membranes were thereafter blocked 30 minutes with PBSMT (PBS 1ϫ, 5% nonfat milk, and 0. bought from Santa Cruz Biotechnologies (Santa Cruz, CA). Specificity of the rabbit polyclonal antibody (1:2000) used against MYOC has been described.
14 Immunoprecipitation COS-7 cells, plated at a density of 1.2 ϫ 10 6 cells per 100-mm culture dish, were harvested 48 hours after cDNA transfections. Cells were washed twice with ice-cold PBS and lysed in 1 mL lysis buffer (50 mM Tris-HCl [pH 7.4], 150 mM sodium chloride, 1% Nonidet P-40, 0.5% sodium deoxycholate, protease inhibitor cocktail tablets [Complete; Roche], and 0.7 g/mL pepstatin; Sigma-Aldrich). The homogenized suspensions were centrifuged 10 minutes at 12,000g and supernatants precleared at least 3 hours with 50 L protein A-agarose (Roche). Agarose beads were then pelleted and supernatants transferred to fresh microcentrifuge tubes. Precleared samples were subsequently incubated for 1 hour on a rocking platform with 5 g of the anti-His antibody (Santa Cruz Biotechnologies) before 50 L of protein A-agarose was added for at least 3 hours. Protein complexes were collected by centrifugation and the supernatants removed. Beads were washed twice with lysis buffer, twice with washing buffer 2 (50 mM Tris-HCl [pH 7.4], 300 mM sodium chloride, 0.1% Nonidet P-40, and 0.05% sodium deoxycholate) and finally once with washing buffer 3 (50 mM Tris-HCl [pH 7.4], 0.1% Nonidet P-40, and 0.05% sodium deoxycholate) before analysis of the immunoprecipitated proteins by Western blot analysis.
RESULTS
Myocilin Oligomerization Status
To test for interactions compatible with dominant negative effects, we first investigated the oligomerization status of myocilin protein in human AH and HTM tissues, using Western blot analysis under nonreducing conditions. We optimized visualization of the bands of more than 150 kDa by resolving proteins through Tris-Acetate 3% to 8% protein gels. MYOC protein was detected with a well-characterized rabbit polyclonal antibody developed against the whole protein.
14 As depicted in Figure  1A (lanes 1 and 4), MYOC immunoreactivity displayed migration patterns that were highly similar in HTM tissues and AH. Immunoreactive bands were detected at approximately 116, 150, and 180 kDa and as several complexes migrating at/and above 200 kDa. AH and HTM obtained from five additional donors, aged 67 to 83 years, were also tested (data not shown). The samples produced migration patterns identical with those shown in Figure 1A , with the 150-kDa band consistently stronger in AH than in HTM (Fig. 1A , compare lane 4 to lane 1). Because the MYOC gene encodes a 504-aa polypeptide with a theoretical molecular mass of 56.9 kDa, our experiments suggested that the different complexes observed in nonreducing conditions may be oligomers formed by two or more MYOC polypeptide(s) and/or by one MYOC polypeptide associated with other proteins.
We next investigated the stability of the HTM and AH myocilin complexes after various denaturing conditions. Boiling and SDS concentration up to 2% had no effect on complex patterns (data not shown). On the contrary, addition of 100 mM of the reducing agent dithiothreitol (DTT) to protein extracts completely disrupted the complexes, showing that disulfide bonds are essential for stabilization of myocilin protein complexes. As depicted in Figure 1B , myocilin was detected in HTM and AH as a doublet migrating at approximately 55 and 57 kDa after DTT treatment. This doublet probably represents glycosylated and unglycosylated forms of the protein. 32, 33, 41 To establish an in vitro system in which we could assess the nature of the oligomers as well as that of the doublet, the pRc-MYOC expression vector encoding WT myocilin was transiently transfected into the COS-7 and iHTM cell lines. These two cell lines were chosen because they did not produce detectable endogenous immunoreactive MYOC protein. Fortyeight hours after transfection, cellular extracts and culture media from COS-7 and iHTM cells were analyzed by immunoblot assay. MYOC migration patterns in cellular extracts and culture media from both cell lines were found to be almost identical with those observed in AH and HTM tissues, with the WT and 2.5 g of HTM tissues were resolved on Tris-acetate 3% to 8% protein gels, and 10 L of both culture media (COS-7 and iHTM cells) and 5 L of AH were analyzed. (B) Myocilin protein from AH and HTM tissues was analyzed under reducing conditions using 5 L AH and 2.5 g HTM tissues, both treated with 100 mM DTT. Reduced proteins were resolved on TrisAcetate 7% protein gel, and MYOC was detected using our polyclonal antibody.
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IOVS, October 2004, Vol. 45, No. 10 exception of the 150-kDa band, which was not detected in iHTM cells (Fig. 1A, lanes 3 and 6) . The COS-7 and iHTM cell lines were therefore selected to investigate further the nature of MYOC immunoreactive complexes in vitro.
Myocilin Glycosylation Status
Because myocilin polypeptide contains several potential sites for N-and O-glycosylation, 14 we determined whether one of these posttranslational modification mechanisms was involved in generating the distinct myocilin isoforms observed as doublets in denaturing conditions. COS-7 cells were transfected with MYOC WT cDNA for 12 hours before a 36-hour incubation period with the antibiotic tunicamycin (an inhibitor of the dolichol-dependent N-glycoside sugar chain biosynthesis). Western blot analysis under reducing conditions revealed that the inhibitor prevented the synthesis of the 57-kDa monomer ( Fig. 2A, lane 2) , suggesting that oligosaccharides were linked to the 55-kDa isoform. The nature of this (these) link(s) was then investigated by transfecting the cells with the WT construct and treating the cellular extracts with specific glycosidases before protein analysis. As depicted in Figure 2A (lane 3) , treatment with the N-glycosidase PNGase F, which releases asparagine-linked oligosaccharides, removed all carbohydrates from the polypeptide backbone of the 57-kDa monomer, leaving intact the 55-kDa isoform. In contrast, treatment with O-glycosidase did not alter the migration pattern of either isoform (Fig. 2A, lane 4) , supporting that oligosaccharides were linked to the 55-kDa isoform solely by an N-glycoside chain. The sensitivity of the 57-kDa monomer to PNGase F digestion was also observed in HTM and AH (Figs. 2B, 2C , respectively), demonstrating that, in vivo, myocilin also formed an N-glycosylated polypeptide. Because MYOC harbored only one potential site for N-glycosylation at Asn57 ( 57 NESS), we then mutated this amino acid to a tyrosine residue. Transfection and analysis of this recombinant revealed that MYOC N57Y cDNA generated only one 55-kDa isoform, the secretion of which was not altered by its lack of glycosylation (Fig. 2D, lane  2) . These results established that the 57-kDa monomer was generated by the addition of an N-amino glycan to the Asn57 residue of the 55-kDa monomer.
Wild-type-Mutant Myocilin Protein Interactions
To investigate whether wild-type myocilin interacts with its disease-causing mutant counterparts, we designed doubleepitope tagging procedures that detected complexes made of at least two MYOC polypeptides. Briefly, different combinations of His-tag and Myc-tag MYOC cDNAs (MYOC WT-His , MYOC WT-Myc , MYOC K423E-Myc , or MYOC Q368X-Myc ) were transfected into COS-7 cells. Forty-eight hours after transfection, newly generated proteins were immunoprecipitated with an antibody raised against a six histidines (His-tag) component added to the C-terminal of myocilin protein, resolved on a 7% Tris-acetate protein gel under nonreducing conditions and visualized by immunoblotting using an anti-Myc antibody specific to the 11-aa Myc-tag epitope added to the C-terminal of a second MYOC polypeptide. When detected, MYOC complexes thus contained at least one His-tag and one Myc-tag myocilin polypeptide. Tagging the C terminus of MYOC polypeptides with a His-tag or a Myc-tag antigenic component did not interfere with their secretion or alter their migration patterns when analyzed with our anti-myocilin polyclonal antibody (Fig. 3A) . To validate the specificity of our double-epitope tagging procedures, we tested for cross-reactivity protein extracts obtained from COS-7 cells transfected with either His-tag or Myc-tag MYOC cDNA alone (Fig. 3B, lanes 4 and 5, respectively). In these conditions, no immunoreactive signal was detected when anti-His-tag immunoprecipitation was performed followed by anti-Myc-tag immunoblot analysis.
We first examined whether WT myocilin interacts with itself. COS-7 cells were transfected with equal quantities of MYOC WT-His and MYOC WT-Myc cDNAs, and our double-epitope tagging procedures was performed on cellular extracts. As depicted in Figure 3B , lane 1, several WT-His/WT-Myc MYOC complexes were detected. They ranged from approximately 116 kDa to more than 200 kDa. Shorter time exposures of the autoradiograms (Ͻ20 seconds) revealed immunoreactive migration patterns similar to those displayed in Figure 1 (data not shown). Because the WT and K423E proteins migrated, under reducing conditions, at approximately 55 to 57 kDa (Fig. 3C,  lanes 1 and 3) , the 116-kDa complex (Fig. 3B, lane 1) thus resulted from homodimerization between two MYOC WT polypeptides, whereas complexes of more than 180 kDa were generated by two MYOC polypeptides interacting together with an additional myocilin entity(ies) and/or in association with other proteins.
We next investigated whether interactions also occur between wild-type MYOC and glaucoma-causing mutants. We first cotransfected COS-7 cells with different ratios of untagged MYOC WT and MYOC Q368X cDNAs. The MYOC Q368X variant is the most common mutation associated with adult-onset primary open-angle glaucoma, carried by more than 1% of all patients with POAG. 12, 22 Because this mutant cDNA yielded two truncated polypeptides of approximately 42 and 44 kDa (Fig. 3C, lane 2 Figure 3D , lanes 1 and 5, when MYOC WT and MYOC Q368X recombinants were transfected alone, they formed homodimers migrating at approximately 116 and 84 kDa, respectively. In cells transfected simultaneously with both cDNAs, a novel immunoreactive complex of intermediate size was produced at approximately 96 kDa (Fig. 3D, lane 3) . This newly generated complex (Fig. 3B, lanes 2 and 3, respectively) were detected as multiple bands migrating at and more than 200 kDa and as heterodimers at approximately 116 and 96 kDa, respectively (Fig. 3B, lanes 2  and 3) . Taken together, our results demonstrate that WT MYOC interacted with itself and with the K423E and Q368X glaucoma-causing mutants generating homo-and heterodimers as well as multiple high molecular weight hetero-oligomers, alone and/or in association with other proteins.
Myocilin Secretion Studies
Several studies demonstrated that WT myocilin protein was secreted from ocular and nonocular cells in culture, whereas variations affecting the olfactomedin domain, associated or not with glaucoma, remained sequestered intracellularly. 30, 32, 33, 35 In these experiments, protein analysis was mostly performed in denaturing conditions and did not investigate whether disease-causing mutants, including the Q368X and K423E mutations, blocked the secretion of the WT protein by interacting with it. To assess whether myocilin mutants block secretion of their wild-type counterpart when forming hetero-oligomers, COS-7 cells were transfected with increasing concentrations of pRc-MYOC K423E-Myc in the presence of decreasing amounts of pRc-MYOC WT-His . Forty-eight hours after transfection, Myc-tag or His-tag immunoreactivities were measured in extracellular media and in cellular extracts. Using specific epitopes for each transfected cDNA allowed us to assess the contribution of each protein to the oligomers. As expected, when WT and mutant proteins were transfected in the absence of their partners, both were highly expressed in COS-7 cellular extracts (Figs. 4A, lane 1; 4B, lane 5). On the contrary, when extracellular media of this experiment were tested, no expression of the K423E-Myc mutant polypeptide was detected outside the cell (Fig. 4D, lane  5) , whereas high levels of wild-type MYOC WT-His protein were observed in the media samples (Fig. 4C, lane 1) . The K423E-Myc mutant polypeptide therefore remained sequestered within the cells. Indeed, when we investigated the presence of the Myc epitope attached to the K423E mutant, no mutant protein was detected in the extracellular medium in any of the samples tested (Fig. 4D, lanes 1-5) . To demonstrate that the failure to detect the Myc epitope outside the cells was not caused by inefficient transfection, protein transfer or visualization procedures, culture media containing MYOC WT-Myc was processed along with the WT-His/K423E-Myc samples (Fig. 4D,  lane 6) . Increasing the ratios of the K423E-Myc proteins while decreasing that of the WT-His progressively hampered secretion of the latter (Fig. 4C, lanes 2, 3, 4) . However, it is noteworthy that high expression levels of the K423E-Myc protein did not totally prevent the secretion of MYOC WT-His , as the wild-type protein was still detected in extracellular media even at a WT-His to K423E-Myc cDNA ratio of 25% to 75% (Fig. 4C,  lane 4) .
As depicted in Figures 3B and 3D , dimerization between one WT polypeptide and one Q368X molecule generated an intracellular immunoreactive complex migrating at approximately 96 kDa. To assess whether WT/Q368X heterodimers remain sequestered within the cellular compartment as observed for the WT/K423E complexes, we searched for these characteristic 96-kDa protein bands in extracellular media of Figure 3D (lane 5), the mutant polypeptide was efficiently produced by COS-7 cells but was not detected in extracellular media (Fig. 5, lane 5) . Furthermore, the 96-kDa WT/Q368X heterodimers were not detected outside the cells when both proteins were coexpressed at various ratios (Fig. 5, lanes 2, 3,  4) . As for the K423E mutant, we also noticed that high expression level of MYOC Q368X progressively hampered, but did not totally block, the secretion of MYOC WT (Fig. 5, lane 4) . These results clearly indicate that WT/mutant complexes were not secreted, in a similar fashion as the mutant/mutant, whereas the WT/WT oligomers still retained the capacity to be released in the medium.
DISCUSSION
Our studies showed that wild-type myocilin protein in its native form displayed multiple complexes ranging from approximately 116 kDa to more than 200 kDa. These complexes were highly similar in HTM and in transfected COS-7 and iHTM cell lines. In AH, an additional 150-kDa immunoreactive band was also consistently observed, increasing the total number of AH complexes to seven migrating at approximately 116, 150, 180, and 200 kDa and above 250 kDa. Our data were in close agreement with gel filtration experiments performed by Fautsch and Johnson 28 who reported in human AH, myocilin immunoreactive complexes ranging in size from 120 to 180 kDa with a peak of activity at 150 kDa. In contrast, in bovine and monkey AH, gel filtration studies performed by Russel et al. 31 demonstrated that most myocilin immunoreactivity migrates in protein fractions above 250 kDa. Such discrepancies may be related to species-specific forms of myocilin or to the less disruptive conditions used by Russel et al. during their gel filtration experiments.
Several studies have suggested that myocilin protein may associate with itself. 14, 28, 31, 33 Other investigations also demonstrated that the protein may interact with specific extracellular matrix proteins 26, 27 or with optimedin, an olfactomedin-related protein. 42 Our experiments clearly showed that two myocilin monomers preferentially interacted to generate homodimers that migrated at approximately 116 kDa. We also showed that complexes at or above 180 kDa contained at least two myocilin moieties, which may then interact with different polypeptides and/or with themselves to generate larger homoand/or hetero-oligomers. At present, we cannot differentiate between these processes, but further experiments using immunoprecipitation and/or purification columns combined with mass spectrometry analysis should help to elucidate their compositions.
Myocilin glycosylation studies revealed that the protein was partially N-glycosylated at asparagine 57, leading to the formation of two isoforms migrating at 55 and 57 kDa, as already observed. 32, 33, 41 Different combinations between these two isoforms may explain the formation of several dimeric forms migrating at slightly different positions, as observed for the wild-type 116 to 120 kDa (Fig. 3D, lane 1) and for the Q368X 82-to 86-kDa (Fig. 3D, lane 5 ) dimer bands. The reason for this incomplete glycosylation state of myocilin may be competition between N-glycosylation and disulfide bond formation, as previously observed with some proteins-for example, the proteins Wingless, 43 carboxypeptidase Y 44 or hemagglutinin-neuraminidase glycoprotein of the Newcastle disease virus. 45 MYOC self-interaction is likely to be mediated through its N-terminal region, which is coiled-coil rich. 14, 28, 32, 33 In agreement with this hypothesis, we clearly demonstrated that myocilin oligomerization was not impaired by the C-terminal Q368X or K423E mutations, because these proteins were detected as several homo-oligomers migrating near and over 200 kDa and as homodimers of ϳ82 and 116 kDa, respectively (Figs. 3D, lane 5; 4B lane 5) . Furthermore, we found that these disease-causing mutants interacted with the wild-type protein to yield numerous hetero-oligomers and heterodimers. That MYOC Q368X did not encode the phylogenetically conserved cysteine 433 suggests that this C-terminal cysteine is not essential for the homo-and hetero-oligomerization process. Our findings may be extended to other olfactomedin domain variations, associated or not with glaucoma. Indeed, preliminary experiments in our laboratory have demonstrated that several mutations in this domain, for instance the P370L and Y437H glaucoma-causing mutant polypeptides, 9, 12 form heterodimers with their wild-type counterpart, which remain sequestered intracellularly (Gobeil S, et al. manuscript in preparation).
Several studies have reported that mutations located within the olfactomedin-like domain of myocilin inhibit its secretion. 30, 33, 35 However, these reports did not investigate whether these disease-causing mutants hamper secretion of their wild-type counterpart by directly interacting with it. Using our double-epitope strategy and protein migration under nonreducing conditions, we observed that the Q368X and K423E homo-oligomers remained sequestered within transfected COS-7 cells. More important, heteromeric complexes formed between WT and mutant polypeptides also remained sequestered within the cells. Intracellular sequestration of wild-type proteins by its mutant counterparts has been demonstrated for several disease-causing proteins. For example, coexpression of the human anion exchanger (AE1), a membrane glycoprotein, with a truncated variant missing 11 amino acids of the carboxyl end results in the formation of heterocomplexes and in the retention of these within the intracellular compartment. This mechanism leads to an autosomal dominant form of the distal renal tubular acidosis (dRTA) disease. 46 Furthermore, aquaporin (AQP)-2, a protein implicated in water reabsorption interacts with its counterpart E258K to produce complexes not exported to the membranes, causing an autosomal dominant form of diabetes insipidus. 47 Mechanisms leading to glaucoma once the WT/mutant and mutant/mutant myocilin oligomers remained sequestered within the cell were not investigated in the present study. However, it is well recognized that mutant membrane and extracellular proteins that fail to fold and/or to oligomerize correctly are often retained within the endoplasmic reticulum (ER) compartment. 48, 49 In agreement with this model, Caballero and Borras 32 presented evidence that a truncated form of myocilin (aa 1-344) was not processed correctly in the ER and accumulated in insoluble aggregates, and Joe et al. 50 demonstrated that mutant myocilin was concentrated into fine punctate aggregates in the ER. More recently, Liu and Vollrath 51 have shown that several disease-causing myocilin mutants also accumulate in the ER and are prone to aggregate, leading to cell toxicity.
Several genetic 20, [52] [53] [54] and biochemical lines of evidence 30, 32, 50, 55 have suggested that autosomal dominant POAG-linked myocilin mutations may act through a pathologic gain-of-function mechanism caused by the intracellular accumulation of mutant proteins. Our results, showing for the first time that WT and mutant myocilin proteins interact and that these heterocomplexes are not secreted, support this hypothesis. However, the asymptomatic condition of the K423E homozygote carriers remains puzzling. As determined by us and Jacobson et al., 30 the K423E protein remained sequestered within cells when expressed in an homozygotic fashion. Thus, the unaffected condition of the K423E/K423E carriers does not result from homoallelic complementation, 56 a process that would have restored the normal secretion of this mutant protein, but may be explained by metabolic interference. Indeed in 1980, Johnson 57 considered dominant negative effects to propose a mechanism called metabolic interference that accounted for hypothetical forms of simple inheritance in which the heterozygote alone was affected. Metabolic interference assumed a one-locus mechanism in which a wild-type allele A and a mutant allele AЈ interact so that homozygosity for either allele has no phenotypic consequence, but the heterozygous state AAЈ leads to a deleterious defect, due to interference between the protein products of the two different alleles. To account for metabolic interference, we thus hypothesize that the K423E homomeric complexes may be degraded by the ER-associated degradation (ERAD) pathway in the cytosol. 58 In contrast, the WT/K423E complexes may not be subjected to this degradation pathway. Over the years, accumulation of these abnormal hetero-oligomers could lead to the malfunction of myocilin-expressing cells and finally to POAG through a dominant negative effect. This mechanism could involve a variety of processes including an activation of the stress apoptotic pathways. Experiences investigating the turnover rates of the homo-and heteromeric mutant complexes should further our understanding of the mechanisms underlying myocilin-associated glaucoma.
